Sarcoma
Welcome,         Profile    Billing    Logout  
 515 Companies   302 Products   302 Products   167 Mechanisms of Action   1404 Trials   125634 News 


«12...15071508150915101511151215131514151515161517...15771578»
  • ||||||||||  Trial primary completion date:  MMS-TM: Validation of MMS Test for Cancer Monitoring (clinicaltrials.gov) -  Mar 13, 2017   
    P=N/A,  N=100, Recruiting, 
    Trial primary completion date: Oct 2017 --> Oct 2018 Trial primary completion date: Dec 2016 --> Dec 2017
  • ||||||||||  Cometriq (cabozantinib capsule) / Exelixis, Ipsen, Cabometyx (cabozantinib tablet) / Exelixis
    Enrollment change, Trial primary completion date:  Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma (clinicaltrials.gov) -  Mar 13, 2017   
    P2,  N=90, Suspended, 
    N=45 --> 0 | Not yet recruiting --> Withdrawn N=64 --> 90 | Trial primary completion date: Jun 2016 --> Jul 2017
  • ||||||||||  Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma
    Journal:  Efficacy of trabectedin for the treatment of liposarcoma. (Pubmed Central) -  Mar 12, 2017   
    N=64 --> 90 | Trial primary completion date: Jun 2016 --> Jul 2017 Trabectedin is an important new addition to the limited treatment options currently available for STS, especially for patients with liposarcoma that have progressed on standard chemotherapeutic regimens.
  • ||||||||||  Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
    Trial initiation date, Myeloid-derived suppressor cells:  Dendritic Cell Vaccine for Children and Adults With Sarcoma (clinicaltrials.gov) -  Mar 10, 2017   
    P1,  N=56, Recruiting, 
    Trial primary completion date: Jun 2016 --> Sep 2017 Initiation date: Jul 2012 --> Jan 2014
  • ||||||||||  docetaxel / Generic mfg., gemcitabine / Generic mfg.
    Journal:  Uterine sarcoma with ambiguous histomorphology: A case report. (Pubmed Central) -  Mar 9, 2017   
    Given the poorer locoregional outcomes of patients previously subjected to pelvic RT, meticulous re-administration of RT might improve locoregional control while leading to less toxicity in these patients. Ancillary studies, such as immunohistochemistry and molecular testing, aid in accurate subcategorization of uterine sarcomas with ambiguous histomorphology.
  • ||||||||||  Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, Lynparza (olaparib) / Merck (MSD), AstraZeneca
    Enrollment closed, Enrollment change, PARP Biomarker, Metastases:  Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS) (clinicaltrials.gov) -  Mar 9, 2017   
    P1,  N=50, Active, not recruiting, 
    Not yet recruiting --> Recruiting | Phase classification: PN/A --> P Recruiting --> Active, not recruiting | N=40 --> 50
  • ||||||||||  Review, Journal:  Molecular Imaging and Precision Medicine in Head and Neck Cancer. (Pubmed Central) -  Mar 9, 2017   
    Molecular imaging using PET plays an important role in assessing the biologic behavior of HN cancer with the goal of delivering individualized cancer treatment. This review summarizes recent genomic discoveries in HN cancer and their implications for functional PET imaging in assessing response to targeted therapies, and drug resistance mechanisms.
  • ||||||||||  Journal:  Cytotoxic monoterpenoid indole alkaloids from Alstonia yunnanensis Diels. (Pubmed Central) -  Mar 9, 2017   
    The isolated compounds were tested in vitro for cytotoxic potential using eight tumor cell lines. As a result, alkaloids 4-6 exhibited cytotoxicities against all tested tumor cell lines, especially against osteosarcoma cell lines (SOSP-9607, MG-63, Saos-2, M663) with IC50values<6μM.
  • ||||||||||  Inlyta (axitinib) / Pfizer, Keytruda (pembrolizumab) / Merck (MSD)
    Trial primary completion date, Metastases:  Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas (clinicaltrials.gov) -  Mar 8, 2017   
    P2,  N=30, Recruiting, 
    As a result, alkaloids 4-6 exhibited cytotoxicities against all tested tumor cell lines, especially against osteosarcoma cell lines (SOSP-9607, MG-63, Saos-2, M663) with IC50values<6μM. Trial primary completion date: Mar 2021 --> Mar 2019
  • ||||||||||  Votrient (pazopanib) / Novartis, BeiGene
    Trial primary completion date, Metastases:  Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer (clinicaltrials.gov) -  Mar 7, 2017   
    P2,  N=39, Recruiting, 
    Use of templates or checklists improves completeness of reports. Trial primary completion date: May 2017 --> May 2018
  • ||||||||||  sapanisertib (CB-228) / Calithera
    Enrollment open, Trial primary completion date, IO biomarker, Surgery:  Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma (clinicaltrials.gov) -  Mar 7, 2017   
    P=N/A,  N=40, Recruiting, 
    Trial primary completion date: May 2017 --> May 2018 Suspended --> Recruiting | Trial primary completion date: Dec 2016 --> Dec 2018
  • ||||||||||  Journal:  Thoracolumbar spinal cord tolerance to high dose conformal proton-photon radiation therapy. (Pubmed Central) -  Mar 5, 2017   
    Our clinical and dosimetric data suggest that the noted dose constraints are safe and acceptable with regard to spinal cord complications. Pre-existing disease characteristics, surgical complications, as well as tumor progression, appear to be more important factors when it comes to spinal cord toxicity.
  • ||||||||||  Mekinist (trametinib) / Novartis, Koselugo (selumetinib) / Merck (MSD), AstraZeneca
    Journal:  Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review. (Pubmed Central) -  Mar 5, 2017   
    This has translated into a multitude of important preclinical studies and clinical trials that are currently underway to find effective therapeutic drugs for KRAS mutant lung cancer. Ultimately, better therapeutics need to be engineered to arrive at RAS-driven precision medicine.
  • ||||||||||  sulindac / Generic mfg., Erivedge (vismodegib) / Roche, sulfasalazine / Generic mfg.
    Journal:  Shh and p50/Bcl3 signaling crosstalk drives pathogenesis of BCCs in Gorlin syndrome. (Pubmed Central) -  Mar 4, 2017   
    We posit that Ptch1+/-/SKH-1 mice are a novel and relevant animal model for NBCCS. Understanding mechanisms that govern genetic predisposition to BCCs should facilitate our ability to identify and treat NBCCS gene carriers, including those at risk for sporadic BCCs while accelerating development of novel therapeutic modalities for these patients.
  • ||||||||||  Farydak (panobinostat) / Secura Bio
    Trial completion, Enrollment change, Combination therapy, Metastases:  Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers (clinicaltrials.gov) -  Mar 3, 2017   
    P1,  N=38, Completed, 
    In a minority of cases, tumor persists and salvage treatments should be considered. Active, not recruiting --> Completed | N=50 --> 38
  • ||||||||||  Phase classification, Trial termination, Trial primary completion date:  Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis (clinicaltrials.gov) -  Mar 3, 2017   
    P=N/A,  N=4, Terminated, 
    N=84 --> 107 | Trial primary completion date: Mar 2018 --> Dec 2018 Phase classification: P1 --> P=N/A | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2016 --> Jun 2016; Slow accrual
  • ||||||||||  sapanisertib (CB-228) / Calithera
    Enrollment open:  Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas (clinicaltrials.gov) -  Mar 3, 2017   
    P2,  N=33, Recruiting, 
    Phase classification: P1 --> P=N/A | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2016 --> Jun 2016; Slow accrual Not yet recruiting --> Recruiting
  • ||||||||||  Review, Journal:  Advances in Bone-targeted Drug Delivery Systems for Neoadjuvant Chemotherapy for Osteosarcoma. (Pubmed Central) -  Mar 2, 2017   
    Therefore, determining how to combine new, polymolecular and multi-pathway targets is an important research aspect of designing new bone-targeted drug delivery systems in future studies. The purpose of this article was to review the status of research on targeted therapy for osteosarcoma and to summarize the progress made thus far in developing bone-targeted drug delivery systems for neoadjuvant chemotherapy for osteosarcoma with the aim of providing new ideas for highly effective therapeutic protocols with low toxicity for patients with osteosarcoma.
  • ||||||||||  Journal:  Presacral Myelolipoma: Diagnosis on Imaging With Pathologic and Clinical Correlation. (Pubmed Central) -  Mar 1, 2017   
    The efficacy of SLA in this setting may be augmented by adjuvant hypofractionated SRS. The combination of a well-encapsulated fat-containing presacral mass, lack of coinciding hematologic disease, and uptake on sulfur colloid scintigraphy support the diagnosis of a presacral myelolipoma.
  • ||||||||||  imatinib / Generic mfg.
    Trial primary completion date, Stroma:  Five Year Adjuvant Imatinib Mesylate (Gleevec (clinicaltrials.gov) -  Mar 1, 2017   
    P2,  N=91, Active, not recruiting, 
    The combination of a well-encapsulated fat-containing presacral mass, lack of coinciding hematologic disease, and uptake on sulfur colloid scintigraphy support the diagnosis of a presacral myelolipoma. Trial primary completion date: May 2018 --> Apr 2017
  • ||||||||||  everolimus / Generic mfg.
    Trial primary completion date, Metastases:  Treatment of Patients With RAD001 With Progressive Sarcoma (clinicaltrials.gov) -  Mar 1, 2017   
    P2,  N=71, Active, not recruiting, 
    Trial primary completion date: May 2018 --> Apr 2017 Trial primary completion date: Dec 2016 --> Dec 2017